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1. INTRODUCTION {#cam42600-sec-0001}
===============

Colorectal cancer is one of the most serious illnesses in both sexes. It has been recognized as the second and third common cancers in females and males, respectively.[1](#cam42600-bib-0001){ref-type="ref"}, [2](#cam42600-bib-0002){ref-type="ref"}, [3](#cam42600-bib-0003){ref-type="ref"} Incidence and mortality of colorectal cancer (CRC)was about 6.1% of new cancer cases and was around 9.2% of cancer death based on Global Cancer Statistics 2018.[4](#cam42600-bib-0004){ref-type="ref"} Its incidence is three times higher in developed countries than developing counters.[4](#cam42600-bib-0004){ref-type="ref"} CRC imposes enormous global burden which could be related to aging and population growth, socioeconomic status, diet, life styles, and habits including smoking, western diet, and physical activity.[5](#cam42600-bib-0005){ref-type="ref"}, [6](#cam42600-bib-0006){ref-type="ref"}, [7](#cam42600-bib-0007){ref-type="ref"} Early diagnosis of CRC leads to lesser treatment cost besides better survival and prognosis.[8](#cam42600-bib-0008){ref-type="ref"} Early prognosis or diagnosis of CRC is also important in cancer survival. Nine of 10 people with CRC would have more than 5 years of survival, if the diagnosis is performed at the stage one while diagnosis in the last stage leads to merely 1 year of survival. For this purpose, finding novel biomarkers for noninvasive early diagnosis of CRC will be crucial in disease treatment.

Some risk factors of CRC including diet and smoking could be modified in contrast to genetic factors.[9](#cam42600-bib-0009){ref-type="ref"}, [10](#cam42600-bib-0010){ref-type="ref"}, [11](#cam42600-bib-0011){ref-type="ref"} MicroRNAs (miRNAs) are important genetic factors which are regulating around 60% of human protein‐coding genes.[12](#cam42600-bib-0012){ref-type="ref"} It is believed that miRNAs play an important role in the pathogenesis of CRC.[13](#cam42600-bib-0013){ref-type="ref"} miRNA polymorphisms might participate in cancer prognosis through their effect on miRNA gene transcription, processing, expression, and target selection.[14](#cam42600-bib-0014){ref-type="ref"}, [15](#cam42600-bib-0015){ref-type="ref"}, [16](#cam42600-bib-0016){ref-type="ref"} A meta‐analysis in 2016 has been implemented on the association between miR‐27a rs895819 in the loop of pre‐miRNA and shows that this SNP may be a risk factor for CRC (for instance in allelic model OR = 1.21 \[1.11‐1.31\]).[13](#cam42600-bib-0013){ref-type="ref"} A systematic review and meta‐analysis has been published in 2014 based on the role of two polymorphisms in miR‐146a and in miR‐196a2 on the susceptibility towards CRC. The results revealed that miR‐196a2 polymorphism rs11614913 is associated with the risk of CRC.[17](#cam42600-bib-0017){ref-type="ref"} Another review paper in 2015 described the association of miRNA variants (in miR‐146a, hsa‐miR‐149, and hsa‐miR‐196a2) and CRC and showed that rs2910164 (1.24 \[1.03‐1.49\]) and rs2292832 (1.18 \[1.08‐1.38\]) may increase the risk of CRC, and rs11614913 and rs3746444 (0.57 \[0.34‐0.95\]) may decrease the risk of CRC.[18](#cam42600-bib-0018){ref-type="ref"} In 2017, a review article was published on the risk of CRC and polymorphisms in microRNA gene. Based on these results let‐7, miR‐149, miR‐603, miR‐34b/c, and miR‐146a gene SNPs were associated with CRC.[19](#cam42600-bib-0019){ref-type="ref"}

Polymorphisms in miRNA‐binding sites may also alter the risk and survival of a variety of human complex diseases including CRC.[20](#cam42600-bib-0020){ref-type="ref"}, [21](#cam42600-bib-0021){ref-type="ref"}, [22](#cam42600-bib-0022){ref-type="ref"} miRNA‐binding sites are conserved through evolution and contain lesser polymorphisms.[23](#cam42600-bib-0023){ref-type="ref"} Polymorphisms in these sites can affect miRNA:mRNA interactions and target mRNA expression.[24](#cam42600-bib-0024){ref-type="ref"}, [25](#cam42600-bib-0025){ref-type="ref"} In one study, the association between let‐7 miRNA‐binding site polymorphisms and CRC outcome has been described, based on one miRNA, one database (PubMed), and also CRC risk was not investigated.[26](#cam42600-bib-0026){ref-type="ref"} miRNAs' target site polymorphisms may potentially play a role in the interaction between miRNAs and their target mRNA, which is dependent on the effect of polymorphism on miRNA:mRNA interactions. There was also a meta‐analysis on 3\'UTR polymorphisms and the risk of cancers,[27](#cam42600-bib-0027){ref-type="ref"} but the results were only for two polymorphisms and were not specific for CRC or miRNA‐binding sites. To the best of our knowledge, there is no previous systematic review on the association between miRNA‐binding site polymorphisms and CRC. Therefore, the lack of a comprehensive systematic review focusing on miRNA‐binding site polymorphisms and CRC is obvious.

Because of importance and economic burden of CRC, and regarding the significant role of miRNA‐binding site polymorphisms on CRC according to the previous studies besides lack of a systematic review on this subject, the necessity of such study on association between miRNA‐binding site polymorphisms and CRC, as prognostic markers, is quite clear. For this purpose, the main objective of the current systematic review was to explore and reveal the association of 3\'UTR and miRNA‐binding site polymorphisms with the risk of CRC. The secondary specific objective was to determine the effect of ethnicity on these associations.

2. METHODS AND ANALYSIS {#cam42600-sec-0002}
=======================

The methods of this study have been developed according to the PRISMA‐P 2015 checklist.[28](#cam42600-bib-0028){ref-type="ref"} PRISMA 2009 flow diagram,[29](#cam42600-bib-0029){ref-type="ref"} used to display the flow of document number through the different phases of the study (Figure [1](#cam42600-fig-0001){ref-type="fig"}). The protocol of this systematic review is registered in International Prospective Register for Systematic Reviews (PROSPERO) on January 11, 2018 (Registration ID = CRD42018084094).

![Flow diagram for systematic review](CAM4-8-7477-g001){#cam42600-fig-0001}

2.1. Eligible studies and participants {#cam42600-sec-0003}
--------------------------------------

This study imposed a restriction on the study design. Observational studies (case‐control, cohort, and cross‐sectional), describing the association between miRNA‐binding site polymorphisms and CRC, were eligible for inclusion. Primary documents will be screened according to the PECO criteria (Participants, Exposure, Comparisons, and Outcomes) and objectives of this study. Studies with deviation from Hardy‐Weinberg equilibrium[30](#cam42600-bib-0030){ref-type="ref"} (HWE) and with the lack of required primary data or data for estimating genotype numbers were excluded. This study also applied a restriction on publication date. Only documents published from January 1, 1992 to November 30, 2018 were searched. This restriction was based on two reasons; first: miRNA discovery date, and second: most recent publications were relevant to our study subject. There was no restriction about the language of documents related to the topic of this study. Non‐English languages articles were translated by free language translation services or by a translator. There was also no limitation on age, gender, ethnicity, and method of genotyping. The study did not impose a restriction on colorectal cancer stages (I, II, III, and IV). Colorectal polyps and family‐based case‐control studies were not considered for inclusion.

2.2. MicroRNAs binding site polymorphism {#cam42600-sec-0004}
----------------------------------------

Polymorphisms in miRNA‐binding sites have been reported to be associated with cancers.[31](#cam42600-bib-0031){ref-type="ref"}, [32](#cam42600-bib-0032){ref-type="ref"} These SNPs are conserved through evolution.[23](#cam42600-bib-0023){ref-type="ref"} These sites act as diagnostic and prognostic biomarkers associated with cancer risk and outcome.[33](#cam42600-bib-0033){ref-type="ref"} Their association with susceptibility, outcome, treatment, prognosis, and progression of CRC has also been reported.[20](#cam42600-bib-0020){ref-type="ref"}, [34](#cam42600-bib-0034){ref-type="ref"}, [35](#cam42600-bib-0035){ref-type="ref"}, [36](#cam42600-bib-0036){ref-type="ref"} In this systematic review, studies that evaluated the relationship between miRNA‐binding site polymorphisms and CRC were included and the primary outcome of this review was finding association between miRNA‐binding site polymorphisms and CRC susceptibility. Moreover, subgroup analysis for ethnicity was carried out on association of CRC risk with microRNA‐binding site polymorphisms.

2.3. Search methods for studies identification {#cam42600-sec-0005}
----------------------------------------------

In order to identify the relevant papers on miRNA‐binding site polymorphisms and colorectal cancer, online systematic search (electronic searches) of literature was performed in PubMed, Embase, Scopus, and Web of Science. We developed PubMed search syntax, as the main database, this syntax was adapted to other database. PubMed search syntax was performed by combined medical subject headings (MeSH), Emtree terms, keywords of related papers, also free text words. Key search terms were "colorectal neoplasms," "miRNA," "Polymorphism, Single Nucleotide," and their equivalents (Table [S1](#cam42600-sup-0005){ref-type="supplementary-material"}). To identify more results, we also manually checked references from included primary articles and relevant reviews, conference papers, gray literature, as well as contact with corresponding authors for missing data.

2.4. Data collection {#cam42600-sec-0006}
--------------------

### 2.4.1. Screening for eligible studies {#cam42600-sec-0007}

Screening and eligibility checking was performed in three following steps. First, duplicate documents were removed. Second, for screening, two reviewers independently scrutinize remaining documents by checking title and/or abstract. Third, full texts\' eligibility was independently scrutinized by two reviewers. Any disagreements between two reviewers were resolved by consensus strategy and third‐person strategy.

### 2.4.2. Data extraction and management {#cam42600-sec-0008}

A data extraction form was created and then piloted by two reviewers. This form included the following data: the name of first author, country of study, year of publication, study design, age, gender, ethnicity, names of 3\'UTR or binding site SNPs, genotyping methods, minor allele frequency (MAF), HWE, sample size, matching criteria (such as age and sex), source of controls (HB, hospital base or PB, population base), odds ratio (OR), confidence interval (95% CIs), and other related raw data. In the next step, two reviewers independently extracted data based on the extraction form. Disagreements were resolved by strategies listed above.

2.5. Analysis {#cam42600-sec-0009}
-------------

### 2.5.1. Meta‐analysis {#cam42600-sec-0010}

Meta‐analysis was performed by using R (3.5.2). Odds ratio and 95% CI were used to investigate the associations between each polymorphism in miRNA‐binding site and CRC. The meta‐analysis was performed based on different genetic models (allelic model (A vs a), homozygous model (AA vs aa), heterozygote model (Aa vs aa), AA vs Aa model, dominant model (AA + Aa vs aa), recessive model (AA vs Aa + aa), and overdominant model (Aa vs AA + aa)). All included studies were at the risk of various types of heterogeneity. For exploring possible sources of heterogeneity, included studies were divided according to the type of polymorphisms. For each polymorphism, if sufficient studies were included, subgroup analysis (based on ethnicity) was applied. Odds ratios were estimated by fixed effects model (FEM) or random effects model (REM), according to the heterogeneity level. Level of heterogeneity between primary studies was obtained by the Cochran\'s Q test (*P* \< .05 is statistically significant) and the *I* ^2^ statistic in forest plots. We used the following guide to interpret the amount of heterogeneity: *I* ^2^ \< 25% = low heterogeneity; 25 ≥ *I* ^2^ \< 50% = moderate heterogeneity; 50 ≥ *I* ^2^ \< 75% = sever heterogeneity; 75% ≥ *I* ^2^ = highly sever heterogeneity.

### 2.5.2. Reporting biases and sensitivity analysis {#cam42600-sec-0011}

We used Begg\'s test and Egger\'s regression method to assess the potential publication bias in primary studies. Main results were depicted by funnel plots (for visual assessment). Sensitivity analysis was performed by the leave‐one‐out method.

3. RESULTS {#cam42600-sec-0012}
==========

In the systematic search, at the first stage we found 9221 documents, with 222 polymorphisms in 3′UTR and miRNA‐binding site of genes that were studied for the risk of CRC. Among them we included main polymorphisms in second search for meta‐analysis (these polymorphisms were selected because the meta‐analysis for all included polymorphisms was not possible, also in order to decrease the false positive prediction of miRNA‐binding sites polymorphisms, only polymorphisms that were mentioned in two studies or more were included, one of these studies should report polymorphism in miRNA‐binding site). Twenty‐five polymorphisms were included (rs10082466, rs10434, rs8176318, rs17281995, rs3212986, rs1368439, rs1131445, rs5275, rs61764370, rs712, rs108621, rs696, rs3135500, rs8679, rs16870224, rs731236, rs3025039, rs3025040, rs3025053, rs4648298, rs1801157, rs3742330, rs4846049, rs854551, and rs9138). Second search strategy applied for these polymorphisms, which contained 5170 documents. Finally, we included 54 studies on the role of 3′UTR polymorphisms and 52 studies on the role of miRNA‐binding site polymorphisms and risk of CRC for all the selected polymorphisms (Tables [1](#cam42600-tbl-0001){ref-type="table"} and [2](#cam42600-tbl-0002){ref-type="table"}). Finally, 21 polymorphisms with two or more than two included studies were eligible for final analysis (these studies are shown in detail in Tables [3](#cam42600-tbl-0003){ref-type="table"} and [4](#cam42600-tbl-0004){ref-type="table"}). For rs17281995 polymorphism, the pooled analysis based on three included articles showed significant increased risk of CRC in different genetic models, including homozygote model 2.29 (1.25‐4.19). Seven of 21 included polymorphisms in our meta‐analysis were polymorphisms with more than four included articles (rs731236, rs3025039, rs3212986, rs712, rs5275, rs4648298, and rs1801157). The basic characteristics of studies included in the meta‐analysis are shown following (Table [4](#cam42600-tbl-0004){ref-type="table"}).

###### 

miRNA‐binding sites polymorphisms and colorectal cancer risk (included from first search strategy)

  References                                 Study design   rsID (target miRNA)
  ------------------------------------------ -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [37](#cam42600-bib-0037){ref-type="ref"}   Case‐control   rs10082466 (miR‐27a)
  [38](#cam42600-bib-0038){ref-type="ref"}   Case‐control   rs11466537 (miR‐1193)
  [39](#cam42600-bib-0039){ref-type="ref"}   Case‐control   rs12904 (miR‐200 family: miR‐200c, miR‐429, and miR‐200b)
  [40](#cam42600-bib-0040){ref-type="ref"}   Case‐control   rs12915554 (miR‐185‐3p)
  [41](#cam42600-bib-0041){ref-type="ref"}   Case‐control   rs141178472 (miR‐520a)
  [42](#cam42600-bib-0042){ref-type="ref"}   Case‐control   rs16917496 (miR‐502)
  [43](#cam42600-bib-0043){ref-type="ref"}   Case‐control   rs1710 (miRNA‐binding site polymorphism[a](#cam42600-note-0001){ref-type="fn"})
  [44](#cam42600-bib-0044){ref-type="ref"}   Case‐control   rs2015 (miR‐376a‐5p)
  [45](#cam42600-bib-0045){ref-type="ref"}   Case‐control   rs2737 (miR‐379)
  [46](#cam42600-bib-0046){ref-type="ref"}   Case‐control   rs3135500 (miR‐158, miR‐215, miR‐98, miR‐573)
  [47](#cam42600-bib-0047){ref-type="ref"}   Case‐control   rs11169571 (miR‐1283, miR‐520d‐5p)
  [48](#cam42600-bib-0048){ref-type="ref"}   Case‐control   rs34149860 (miR‐29b)
  [49](#cam42600-bib-0049){ref-type="ref"}   Case‐control   rs4648298 (miR‐21, miR590)
  [50](#cam42600-bib-0050){ref-type="ref"}   Case‐control   rs3814058 (miR‐129‐5p)
  [51](#cam42600-bib-0051){ref-type="ref"}   Case‐control   rs4245739 (miR‐191)
  [52](#cam42600-bib-0052){ref-type="ref"}   Case‐control   rs4804800 (miR‐622, miR‐1238)
  [53](#cam42600-bib-0053){ref-type="ref"}   Case‐control   rs4939827 (miR‐375)
  [54](#cam42600-bib-0054){ref-type="ref"}   Case‐control   rs5275 (miR‐542‐3p)
  [55](#cam42600-bib-0055){ref-type="ref"}   Case‐control   rs61764370 (let‐7)
  [56](#cam42600-bib-0056){ref-type="ref"}   Case‐control   rs61764370 (let‐7)
  [57](#cam42600-bib-0057){ref-type="ref"}   Case‐control   rs696 (miR449a)
  [58](#cam42600-bib-0058){ref-type="ref"}   Case‐control   rs696 (miR‐449a, miR‐34b)
  [36](#cam42600-bib-0036){ref-type="ref"}   Case‐control   rs712 (let‐7)
  [59](#cam42600-bib-0059){ref-type="ref"}   Case‐control   rs712 (miR‐200b, miR‐429, miR‐200c, miR‐193b)
  [60](#cam42600-bib-0060){ref-type="ref"}   Case‐control   rs8679 (miR‐145)
  [61](#cam42600-bib-0061){ref-type="ref"}   Case‐control   rs12997 (miR‐330‐3p), rs1043784 (miR‐584), rs10038999 (miR‐629), rs1129976 (miR‐150)
  [62](#cam42600-bib-0062){ref-type="ref"}   Case‐control   rs712 (let‐7), rs61764370 (let‐7)
  [63](#cam42600-bib-0063){ref-type="ref"}   Case‐control   rs17468, rs2317676 (miRNA‐binding site polymorphisms)
  [64](#cam42600-bib-0064){ref-type="ref"}   Case‐control   rs3135500, rs1368439 (miRNA ‐binding site polymorphisms)
  [65](#cam42600-bib-0065){ref-type="ref"}   Case‐control   rs13347 (miR‐509‐3p), rs10836347, rs11821102 (miRNA‐binding site polymorphisms)
  [66](#cam42600-bib-0066){ref-type="ref"}   Case‐control   rs5186 (miR‐155), rs710100 (miR‐155), rs411103 (miR‐27b)
  [67](#cam42600-bib-0067){ref-type="ref"}   Case‐control   rs847 (miR‐98, let‐7i/f/g), rs848 (miR‐558, miR‐621, let‐7i), rs1295685 (miR‐621)
  [68](#cam42600-bib-0068){ref-type="ref"}   Case‐control   rs7930 (miR‐4273‐5p), rs8117825 (miR‐3126‐5p, miR‐337‐3p), rs16853287 (miR‐128‐3p, miR‐140‐3p)
  [69](#cam42600-bib-0069){ref-type="ref"}   Case‐control   rs1590 (miR‐532‐5p, miR‐768‐3p), rs1434536, rs17023107 (miRNA‐binding site polymorphisms)
  [70](#cam42600-bib-0070){ref-type="ref"}   Case‐control   rs4143815 (miR‐570), rs1059293, rs27194, rs43216 (miRNA‐binding site polymorphisms)
  [71](#cam42600-bib-0071){ref-type="ref"}   Case‐control   rs1062044 (miR‐423‐5p), rs17477864 (miR‐186‐5p), rs3824998 (miR‐221‐3p), rs4768914 (miR‐200c‐3P), rs1046165 (miR‐451a)
  [72](#cam42600-bib-0072){ref-type="ref"}   Case‐control   rs108621 (miR‐193a‐3p, miR‐338‐3p), rs3212986 (miR‐15a)
  [73](#cam42600-bib-0073){ref-type="ref"}   Case‐control   rs3660, rs1044129, rs1053667, rs4901706, rs11337 (miRNA‐binding site polymorphisms)
  [74](#cam42600-bib-0074){ref-type="ref"}   Case‐control   rs1131445 (miR‐135a/135b), rs1051208 (miR‐213), rs743554, rs16870224, rs11515 (miRNA‐binding site polymorphisms)
  [75](#cam42600-bib-0075){ref-type="ref"}   Case‐control   rs1126547 (hsa‐miR‐141, hsa‐miR‐200a), rs2229090 (miR‐1225‐3p, miR‐3123, miR‐3619), rs9914073 (miR‐548c‐3p, miR‐605), rs17339395 (miR‐4299), rs7356 (miR‐3149,miR‐1183), rs1803541 (miR‐568, miR‐802), rs4596 (miR‐518a‐5p, miR‐527, miR‐1205), rs4781563 (miR‐2355‐3p, miR‐4288), rs45522131 (miR‐26a/b, miR‐374a)
  [76](#cam42600-bib-0076){ref-type="ref"}   Case‐control   rs61764370 (let‐7), rs8679 (miR‐145‐3p), rs1804197, rs41116, rs397768, rs4585, rs712, rs16950113 (miRNA‐binding site polymorphisms)
  [22](#cam42600-bib-0022){ref-type="ref"}   Case‐control   rs17281995 (miR‐337, miR‐582, miR‐200a\*, miR‐184, miR‐212), rs3135500 (miR‐158, miR‐215, miR‐98, miR‐573), rs1131445 (miR‐135a, miR‐135b, miR‐143, miR‐18, miR‐18a), rs1368439 (miR‐513, miR‐210, miR‐27b, miR‐27a), rs916055 (miR‐588, miR‐183), rs11677 (miR‐187, miR‐638, miR‐154, miR‐453, miR‐296), rs16870224 (miR‐9, miR‐30a‐3p, miR‐30e‐3p), rs1051690 (miR‐618, miR‐612)
  [77](#cam42600-bib-0077){ref-type="ref"}   Case‐control   rs2147578 (miR‐128‐3p,216a‐3p,3681‐3p), rs112462125 (miR‐197‐3p), rs7844527 (miR‐146a‐5p,146b‐5p), rs7814028 (miR‐5001‐3p,miR‐6819‐3p), rs12677572 (miR‐891a‐5p), rs60719452 (miR‐548‐5p,548ab,548ak,548au‐5p,548ay‐5p,548b‐5p,548d‐5p,548i,548y), rs61095617 (miR‐1307‐5p), rs75511849 (miR‐100‐3p)
  [78](#cam42600-bib-0078){ref-type="ref"}   Case‐control   rs88640,3 (miR‐4647, miR‐588, miR‐125, let‐7), rs4077531, rs3733492, rs12732, rs1532602, rs4071, rs17552409, rs17243454, rs4729655, rs7631009, rs6782006, rs974034, rs7372 (miRNA‐binding site polymorphisms)
  [79](#cam42600-bib-0079){ref-type="ref"}   Case‐control   rs712 (miR‐200b, miR‐429, miR‐200c, miR‐193b), rs709805 (miR‐324‐3p), rs2289965 (miR‐142‐3p, miR‐324‐5p), rs3012518 (miR‐299‐3p), rs2839629 (miR‐18a, miR‐18b), rs904960 (miR‐32, miR‐25, miR‐367, miR‐363), rs3734279 (miR‐203), rs354476 (miR‐125a, miR‐125b), rs495714 (miR‐324‐3p, miR‐196b, miR‐196a), rs1048650 (miR‐22), rs496550 (miR‐363), rs473351 (miR‐182)
  [80](#cam42600-bib-0080){ref-type="ref"}   Case‐control   rs2233921 (miR‐3925‐3p, miR‐3140‐3p, miR‐1825, miR‐1825, miR‐3925‐3p, miR‐3140‐3p), rs971 (miR‐4744, miR‐3154, miR‐610, miR‐4744, miR‐3154, hsa‐miR‐610), rs6997097 (miR‐3605‐5p, miR‐3545‐3p, miR‐3605‐5p, miR‐3545‐3p), rs8191670, rs2740439, rs4639, rs1043180, rs1055678, rs1052536 rs2307285, rs2307294, rs1534862, (miRNA‐binding site polymorphisms)
  [34](#cam42600-bib-0034){ref-type="ref"}   Case‐control   rs2279398 miR‐370, rs1047854, rs11206394, rs1128287, rs1131445, rs12462695, rs15049, rs17111100, rs2275085, rs2283606, rs2839531, rs3135499, rs3757417, rs3803098, rs747343, rs9118 (miRNA‐binding site polymorphisms)
  [81](#cam42600-bib-0081){ref-type="ref"}   Case‐control   rs2155209 (miR‐1296, miR‐296‐5p), rs11226 (miR‐296‐5p, miR‐1296), rs1051669 rs11571475, rs7963551, rs12593359, rs7180135, rs45507396, rs8176318, rs13447749, rs9995, rs14448,rs300171, rs300170, rs3218547, rs10131, rs1051685, rs2440, rs1051677, rs897477, rs2035990 (miRNA‐binding site polymorphisms)

miRNA‐binding site polymorphism: the polymorphism located in miRNA‐binding sites (according to the referenced article).
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###### 

3ʹUTR polymorphisms and colorectal cancer risk (included from first search strategy)

  Reference                                   Study design         rsID
  ------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  [82](#cam42600-bib-0082){ref-type="ref"}    Case‐control         rs1058881
  [83](#cam42600-bib-0083){ref-type="ref"}    Case‐control         rs1059234
  [84](#cam42600-bib-0084){ref-type="ref"}    Case‐control         rs731236
  [85](#cam42600-bib-0085){ref-type="ref"}    Case‐control         rs108621
  [86](#cam42600-bib-0086){ref-type="ref"}    Case‐control         rs142559064
  [40](#cam42600-bib-0040){ref-type="ref"}    Case‐control         rs146588909
  [87](#cam42600-bib-0087){ref-type="ref"}    Case‐control         rs17281995
  [88](#cam42600-bib-0088){ref-type="ref"}    Case‐control         rs1801157
  [89](#cam42600-bib-0089){ref-type="ref"}    Case‐control         rs1801157
  [90](#cam42600-bib-0090){ref-type="ref"}    Case‐control         rs1801157
  [91](#cam42600-bib-0091){ref-type="ref"}    Case‐control         rs2075786
  [44](#cam42600-bib-0044){ref-type="ref"}    Case‐control         rs2241703
  [92](#cam42600-bib-0092){ref-type="ref"}    Case‐control         rs3025039
  [93](#cam42600-bib-0093){ref-type="ref"}    Case‐control         rs3025039
  [94](#cam42600-bib-0094){ref-type="ref"}    Case‐control         rs3025039
  [95](#cam42600-bib-0095){ref-type="ref"}    Case‐control         rs3025039
  [96](#cam42600-bib-0096){ref-type="ref"}    Case‐control         rs3212986
  [50](#cam42600-bib-0050){ref-type="ref"}    Case‐control         rs3732360
  [97](#cam42600-bib-0097){ref-type="ref"}    Case‐control         rs3742330
  [98](#cam42600-bib-0098){ref-type="ref"}    Nested case‐cohort   rs5275
  [99](#cam42600-bib-0099){ref-type="ref"}    Case‐control         rs78378222
  [100](#cam42600-bib-0100){ref-type="ref"}   Case‐control         rs5275
  [101](#cam42600-bib-0101){ref-type="ref"}   Case‐control         rs5275
  [102](#cam42600-bib-0102){ref-type="ref"}   Case‐control         rs57898959
  [103](#cam42600-bib-0103){ref-type="ref"}   Case‐control         rs8176318
  [104](#cam42600-bib-0104){ref-type="ref"}   Case‐control         rs696
  [105](#cam42600-bib-0105){ref-type="ref"}   Case‐control         rs713041
  [106](#cam42600-bib-0106){ref-type="ref"}   Case‐control         rs7579
  [107](#cam42600-bib-0107){ref-type="ref"}   Case‐control         rs8878
  [108](#cam42600-bib-0108){ref-type="ref"}   Case‐control         rs9138
  [109](#cam42600-bib-0109){ref-type="ref"}   Case‐control         rs9138
  [110](#cam42600-bib-0110){ref-type="ref"}   Case‐control         CDX2‐G1312T
  [111](#cam42600-bib-0111){ref-type="ref"}   Case‐control         rs868, rs7591
  [112](#cam42600-bib-0112){ref-type="ref"}   Case‐control         rs5275, rs4648298
  [113](#cam42600-bib-0113){ref-type="ref"}   Case‐control         rs67085638, rs77628730
  [114](#cam42600-bib-0114){ref-type="ref"}   Case‐control         rs4648298, rs5276, rs13306035
  [115](#cam42600-bib-0115){ref-type="ref"}   Case‐control         rs1205, rs3093075
  [116](#cam42600-bib-0116){ref-type="ref"}   Case‐control         rs7975232, rs1544410
  [117](#cam42600-bib-0117){ref-type="ref"}   Case‐control         rs16930073, rs8491, rs854551
  [118](#cam42600-bib-0118){ref-type="ref"}   Case‐control         rs11875, rs1042669, rs4149206
  [119](#cam42600-bib-0119){ref-type="ref"}   Case‐control         rs3025040, rs10434, rs3025053
  [72](#cam42600-bib-0072){ref-type="ref"}    Case‐control         rs735482, rs2336219, rs1052133
  [62](#cam42600-bib-0062){ref-type="ref"}    Case‐control         rs12245, rs12587, rs9266, rs1137282
  [120](#cam42600-bib-0120){ref-type="ref"}   Case‐control         rs3742330, rs10719, rs14035, rs11077
  [121](#cam42600-bib-0121){ref-type="ref"}   Case‐control         rs334348, rs334349, rs1590, rs868, rs420549
  [122](#cam42600-bib-0122){ref-type="ref"}   Case‐control         rs11708581, rs12163565, rs390802, rs123598
  [37](#cam42600-bib-0037){ref-type="ref"}    Case‐control         rs2120132, rs2099902, rs10450310, rs10082466
  [123](#cam42600-bib-0123){ref-type="ref"}   Case‐control         rs4846049, rs1537514, rs3737967, rs4846048
  [124](#cam42600-bib-0124){ref-type="ref"}   Case‐control         rs1137188, rs3025039, rs3025040, rs3025053, rs10434
  [125](#cam42600-bib-0125){ref-type="ref"}   Nested case‐cohort   rs11168267, rs11574113, rs731236, rs3847987, rs11574143
  [66](#cam42600-bib-0066){ref-type="ref"}    Case‐control         rs12009, rs700082, rs1057035, rs10404, rs1939861, rs3757261
  [52](#cam42600-bib-0052){ref-type="ref"}    Case‐control         rs7248637, rs11465421, rs10824792, rs2083771, rs1052972
  [43](#cam42600-bib-0043){ref-type="ref"}    Case‐control         rs1707, rs17179101, rs17179108, rs1063320, rs9380142, rs1610696
  [68](#cam42600-bib-0068){ref-type="ref"}    Case‐control         rs4985036, rs9970671, rs11861556, rs17500814, rs12678, rs9129, rs2561819
  [126](#cam42600-bib-0126){ref-type="ref"}   Case‐control         rs2302821, rs45544737, rs34337770, rs7730368, rs16870224, rs4957343, rs9312555
  [127](#cam42600-bib-0127){ref-type="ref"}   Case‐control         rs10849, rs10890324, rs293796, rs7641176, rs293782, rs293783, rs6809452, rs6544991, rs6720549, rs6713506, rs2537742
  [128](#cam42600-bib-0128){ref-type="ref"}   Case‐control         rs2298753, rs706209, rs13420827, rs6058896, rs3827869, rs1832683, rs4846049, rs9282787, rs9332, rs854571, rs1544468, rs10418, rs757158, rs854551, rs3917577
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###### 

Genotyping and analysis results of polymorphism with less than four eligible studies

  Gene      rsID         Case               Control                References                                  Sig. in genetic models
  --------- ------------ ------ ----- ----- --------- ----- ------ ------------------------------------------- --------------------------------------------
                         CC     GC    GG    CC        GC    GG                                                 Yes[a](#cam42600-note-0002){ref-type="fn"}
  CD86      rs17281995   7      48    137   0         55    164    [87](#cam42600-bib-0087){ref-type="ref"}     
                         24     161   475   8         114   434    [22](#cam42600-bib-0022){ref-type="ref"}     
                         12     75    217   7         67    181    [129](#cam42600-bib-0129){ref-type="ref"}    
                         CC     TC    TT    CC        TC    TT                                                  
  PARP1     rs8679       53     335   687   66        482   873    [76](#cam42600-bib-0076){ref-type="ref"}    No
                         12     60    111   14        86    90     [60](#cam42600-bib-0060){ref-type="ref"}     
                         AA     GA    GG    AA        GA    GG                                                  
  VEGF      rs10434      8      57    214   9         83    213    [119](#cam42600-bib-0119){ref-type="ref"}   No
                         19     143   209   11        93    142    [124](#cam42600-bib-0124){ref-type="ref"}    
                         CC     TC    TT    CC        TC    TT                                                  
  MLH3      rs108621     219    562   311   300       665   428    [85](#cam42600-bib-0085){ref-type="ref"}    No
                         14     62    124   9         59    132    [72](#cam42600-bib-0072){ref-type="ref"}     
                         CC     CT    TT    CC        CT    TT                                                  
  IL‐16     rs1131445    36     110   103   34        159   201    [74](#cam42600-bib-0074){ref-type="ref"}    No
                         65     287   308   53        240   251    [22](#cam42600-bib-0022){ref-type="ref"}     
                         GG     TG    TT    GG        TG    TT                                                  
  IL12B     rs1368439    2      29    61    2         35    68     [64](#cam42600-bib-0064){ref-type="ref"}    No
                         21     188   465   15        164   388    [22](#cam42600-bib-0022){ref-type="ref"}     
                         AA     GA    GG    AA        GA    GG                                                  
  PTGER4    rs16870224   11     130   523   4         116   439    [22](#cam42600-bib-0022){ref-type="ref"}    No
                         2      68    179   14        109   271    [74](#cam42600-bib-0074){ref-type="ref"}     
                         AA     CA    CC    AA        CA    CC                                                  
  *BRCA1*   rs8176318    127    504   484   109       504   560    [103](#cam42600-bib-0103){ref-type="ref"}   No
                         119    445   509   144       634   640    [81](#cam42600-bib-0081){ref-type="ref"}     
                         AA     GA    GG    AA        GA    GG                                                  
  VEGF      rs3025053    0      36    243   0         27    278    [119](#cam42600-bib-0119){ref-type="ref"}   No
                         6      91    274   4         67    175    [124](#cam42600-bib-0124){ref-type="ref"}    
                         AA     CA    CC    AA        CA    CC                                                  
  MTHFR     rs4846049    79     344   373   83        351   371    [123](#cam42600-bib-0123){ref-type="ref"}   No
                         17     157   276   9         113   278    [128](#cam42600-bib-0128){ref-type="ref"}    
                         AA     AC    CC    AA        AC    CC                                                 Yes[b](#cam42600-note-0003){ref-type="fn"}
  SPP1      rs9138       31     138   99    20        102   152    [108](#cam42600-bib-0108){ref-type="ref"}    
                         20     42    38    19        43    50     [109](#cam42600-bib-0109){ref-type="ref"}    
                         AA     GA    GG    AA        GA    GG                                                  
  NOD2      rs3135500    15     37    40    19        48    38     [64](#cam42600-bib-0064){ref-type="ref"}    Yes[c](#cam42600-note-0004){ref-type="fn"}
                         31     42    15    10        43    35     [46](#cam42600-bib-0046){ref-type="ref"}     
                         120    303   243   81        265   209    [22](#cam42600-bib-0022){ref-type="ref"}     
                         GG     TG    TT    GG        TG    TT                                                  
  KRAS      rs61764370   0      66    375   2         35    202    [130](#cam42600-bib-0130){ref-type="ref"}   No
                         1      45    151   2         68    288    [56](#cam42600-bib-0056){ref-type="ref"}     
                         6      167   916   10        215   1200   [76](#cam42600-bib-0076){ref-type="ref"}     
                         AA     AG    GG    AA        AG    GG                                                  
  NFKBIA    rs696        55     181   118   155       480   380    [104](#cam42600-bib-0104){ref-type="ref"}   No
                         233    460   308   212       531   262    [58](#cam42600-bib-0058){ref-type="ref"}     
                         57     58    28    22        62    53     [57](#cam42600-bib-0057){ref-type="ref"}     

VEGF, vascular endothelial growth factor.

Allelic model, OR: 1.28, 95% CI (1.08‐1.52); Recessive model, OR: 2.23, 95% CI (1.22‐4.07); Dominant model, OR: 1.23, 95% CI (1.01‐1.49); Homozygote, OR: 2.29, 95% CI (1.25‐4.19); Heterozygote CC vs GC OR: 2.06, 95% CI (1.10‐3.83).

Overdominant model, OR: 1.59, 95% CI (1.19‐2.12).

AA vs AG OR: 2.50, 95% CI (1.12‐5.57).

John Wiley & Sons, Ltd

###### 

The basic characteristic of included studies (polymorphisms with at least four eligible studies were included)

<table><thead><tr class="header"><th>SNPs</th><th>First author</th><th>Year</th><th>Country</th><th>Population subgroup<a href="#cam42600-note-0005" data-ref-type="fn">a</a></th><th>Case</th><th>Study design</th><th>Gender</th><th>Age</th><th>Sample size (case‐control)</th><th>Genotyping method</th><th>Quality score</th><th>References</th></tr></thead><tbody><tr class="odd"><td>rs731236</td><td>Budhathoki</td><td>2016</td><td>Japan</td><td>East Asian</td><td>CRC</td><td>Nested case‐control</td><td>F/M</td><td>40‐69</td><td>356/708</td><td>TaqMan</td><td>8</td><td><a href="#cam42600-bib-0125" data-ref-type="ref">125</a></td></tr><tr class="even"><td>Takeshige</td><td>2015</td><td>Japan</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>20‐74</td><td>685/778</td><td>PCR‐RFLP</td><td>9</td><td><a href="#cam42600-bib-0131" data-ref-type="ref">131</a></td><td></td></tr><tr class="odd"><td>Park</td><td>2006</td><td>Korea</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>23‐81</td><td>190/318</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0132" data-ref-type="ref">132</a></td><td></td></tr><tr class="even"><td>Hughes</td><td>2011</td><td>Czech Republic</td><td>European</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>&gt;29</td><td>717/615</td><td>KASPar</td><td>8</td><td><a href="#cam42600-bib-0133" data-ref-type="ref">133</a></td><td></td></tr><tr class="odd"><td>Bentley</td><td>2012</td><td>New Zealand</td><td>European</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>199/182</td><td>TaqMan</td><td>7</td><td><a href="#cam42600-bib-0134" data-ref-type="ref">134</a></td><td></td></tr><tr class="even"><td>Gromowski</td><td>2016</td><td>Poland</td><td>European</td><td>CRC</td><td>Case‐control</td><td>—</td><td>—</td><td>195/390</td><td>TaqMan</td><td>4</td><td><a href="#cam42600-bib-0135" data-ref-type="ref">135</a></td><td></td></tr><tr class="odd"><td>Laczmanska</td><td>2014</td><td>Poland</td><td>European</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>32‐87</td><td>157/175</td><td>SNaPshot Multiplex Kit</td><td>6</td><td><a href="#cam42600-bib-0084" data-ref-type="ref">84</a></td><td></td></tr><tr class="even"><td>Flügge</td><td>2007</td><td>Russia</td><td>European</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>29‐85</td><td>256/256</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0136" data-ref-type="ref">136</a></td><td></td></tr><tr class="odd"><td>Mahmoudi</td><td>2010</td><td>Iran</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>14‐90</td><td>160/180</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0137" data-ref-type="ref">137</a></td><td></td></tr><tr class="even"><td>Moossavi</td><td>2017</td><td>Iran</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>100/100</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0138" data-ref-type="ref">138</a></td><td></td></tr><tr class="odd"><td>Safaei</td><td>2012</td><td>Iran</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>112/112</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0139" data-ref-type="ref">139</a></td><td></td></tr><tr class="even"><td>Atoum</td><td>2014</td><td>Jordan</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>93/102</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0140" data-ref-type="ref">140</a></td><td></td></tr><tr class="odd"><td>Alkhayal</td><td>2016</td><td>Saudi Arabia</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>21‐89</td><td>100/100</td><td>Sequencing</td><td>5</td><td><a href="#cam42600-bib-0141" data-ref-type="ref">141</a></td><td></td></tr><tr class="even"><td>Gunduz</td><td>2012</td><td>Turkey</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>43/42</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0142" data-ref-type="ref">142</a></td><td></td></tr><tr class="odd"><td>Yaylım‐Eraltan</td><td>2007</td><td>Turkey</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>—</td><td>—</td><td>26/52</td><td>PCR‐RFLP</td><td>4</td><td><a href="#cam42600-bib-0143" data-ref-type="ref">143</a></td><td></td></tr><tr class="even"><td>Dilmec</td><td>2009</td><td>Turkey</td><td>Middle East</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>56/169</td><td>PCR‐RFLP</td><td>4</td><td><a href="#cam42600-bib-0144" data-ref-type="ref">144</a></td><td></td></tr><tr class="odd"><td>Kupfer</td><td>2011</td><td>USA</td><td>African</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>938/811</td><td>Sequenom MassARRAY</td><td>7</td><td><a href="#cam42600-bib-0145" data-ref-type="ref">145</a></td><td></td></tr><tr class="even"><td>Slattery</td><td>2001</td><td>USA</td><td>Caucasian, African, Hispanic</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>30‐79</td><td>427/366</td><td>PCR‐RFLP</td><td>9</td><td><a href="#cam42600-bib-0146" data-ref-type="ref">146</a></td><td></td></tr><tr class="odd"><td>Ochs‐Balcom</td><td>2008</td><td>USA</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>≥40</td><td>250/246</td><td>TaqMan</td><td>8</td><td><a href="#cam42600-bib-0147" data-ref-type="ref">147</a></td><td></td></tr><tr class="even"><td>Yamaji</td><td>2011</td><td>Japan</td><td>East Asian</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>40‐79</td><td>684/640</td><td>TaqMan</td><td>7</td><td><a href="#cam42600-bib-0148" data-ref-type="ref">148</a></td><td></td></tr><tr class="odd"><td>Peters</td><td>2004</td><td>USA</td><td>European</td><td>Adenoma</td><td>Nested Case‐control</td><td>F/M</td><td>55‐74</td><td>716/727</td><td>PCR‐RFLP</td><td>7</td><td><a href="#cam42600-bib-0149" data-ref-type="ref">149</a></td><td></td></tr><tr class="even"><td>Peters</td><td>2004</td><td>USA</td><td>African</td><td>Adenoma</td><td>Nested Case‐control</td><td>F/M</td><td>55‐74</td><td>763/774</td><td>PCR‐RFLP</td><td>7</td><td><a href="#cam42600-bib-0149" data-ref-type="ref">149</a></td><td></td></tr><tr class="odd"><td>rs30259039</td><td>Hofmann</td><td>2008</td><td>Austria</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>29‐83</td><td>427/427</td><td>TaqMan</td><td>7</td><td><a href="#cam42600-bib-0150" data-ref-type="ref">150</a></td></tr><tr class="even"><td>Wu</td><td>2009</td><td>Germany</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>33‐91</td><td>157/117</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0151" data-ref-type="ref">151</a></td><td></td></tr><tr class="odd"><td>Ungerback</td><td>2009</td><td>Sweden</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>—</td><td>—</td><td>302/336</td><td>MegaBACE™ SNuPe™ Genotyping Kit</td><td>5</td><td><a href="#cam42600-bib-0095" data-ref-type="ref">95</a></td><td></td></tr><tr class="even"><td>Bayhan</td><td>2014</td><td>Turkey</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>—</td><td>—</td><td>43/44</td><td>PCR‐RFLP</td><td>4</td><td><a href="#cam42600-bib-0152" data-ref-type="ref">152</a></td><td></td></tr><tr class="odd"><td>Jannuzzi</td><td>2015</td><td>Turkey</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>103/129</td><td>PCR‐RFLP</td><td>8</td><td><a href="#cam42600-bib-0153" data-ref-type="ref">153</a></td><td></td></tr><tr class="even"><td>Yang</td><td>2017</td><td>China</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>20‐83</td><td>371/246</td><td>iMLDR method</td><td>7</td><td><a href="#cam42600-bib-0124" data-ref-type="ref">124</a></td><td></td></tr><tr class="odd"><td>Bae</td><td>2008</td><td>Korea</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>18‐95</td><td>262/229</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0154" data-ref-type="ref">154</a></td><td></td></tr><tr class="even"><td>Chae</td><td>2008</td><td>Korea</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>21‐89</td><td>465/413</td><td>PCR/DHPLC</td><td>4</td><td><a href="#cam42600-bib-0141" data-ref-type="ref">141</a></td><td></td></tr><tr class="odd"><td>Jang</td><td>2013</td><td>Korea</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>390/492</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0155" data-ref-type="ref">155</a></td><td></td></tr><tr class="even"><td>Lau</td><td>2014</td><td>Malaysia</td><td>South Asian</td><td>CRC</td><td>Case‐control</td><td>—</td><td>40‐90</td><td>130/212</td><td>TaqMan</td><td>5</td><td><a href="#cam42600-bib-0156" data-ref-type="ref">156</a></td><td></td></tr><tr class="odd"><td>Credidio</td><td>2011</td><td>Brazil</td><td>Caucasian, African</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>25‐97</td><td>261/261</td><td>PCR‐RFLP</td><td>4</td><td><a href="#cam42600-bib-0157" data-ref-type="ref">157</a></td><td></td></tr><tr class="even"><td>Wu</td><td>2011</td><td>China</td><td>East Asian</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>18‐75</td><td>224/200</td><td>TaqMan</td><td>8</td><td><a href="#cam42600-bib-0158" data-ref-type="ref">158</a></td><td></td></tr><tr class="odd"><td>rs3212986</td><td>Hou</td><td>2014</td><td>China</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>204/204</td><td>MALDI‐MS</td><td>7</td><td><a href="#cam42600-bib-0159" data-ref-type="ref">159</a></td></tr><tr class="even"><td>Moreno</td><td>2006</td><td>Spain</td><td>_</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>349/300</td><td>APEX</td><td>7</td><td><a href="#cam42600-bib-0160" data-ref-type="ref">160</a></td><td></td></tr><tr class="odd"><td>Ni</td><td>2014</td><td>China</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>213/240</td><td>TaqMan</td><td>8</td><td><a href="#cam42600-bib-0161" data-ref-type="ref">161</a></td><td></td></tr><tr class="even"><td>Yueh</td><td>2017</td><td>Taiwan</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>362/362</td><td>PCR‐RFLP</td><td>7</td><td><a href="#cam42600-bib-0162" data-ref-type="ref">162</a></td><td></td></tr><tr class="odd"><td>Zhang</td><td>2018</td><td>China</td><td>East Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>200/200</td><td>TaqMan</td><td>5</td><td><a href="#cam42600-bib-0072" data-ref-type="ref">72</a></td><td></td></tr><tr class="even"><td>rs712</td><td>Dai</td><td>2016</td><td>China</td><td>Chinese</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>36‐75</td><td>430/430</td><td>iMLDR</td><td>7</td><td><a href="#cam42600-bib-0062" data-ref-type="ref">62</a></td></tr><tr class="odd"><td>Jiang</td><td>2015</td><td>China</td><td>Chinese</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>586/476</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0036" data-ref-type="ref">36</a></td><td></td></tr><tr class="even"><td>Landi</td><td>2012</td><td>Czech Republic</td><td>Czechs</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>717/1171</td><td>KASPar</td><td>7</td><td><a href="#cam42600-bib-0079" data-ref-type="ref">79</a></td><td></td></tr><tr class="odd"><td>Pan</td><td>2014</td><td>China</td><td>Chinese</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>339/313</td><td>PCR‐RFLP</td><td>7</td><td><a href="#cam42600-bib-0059" data-ref-type="ref">59</a></td><td></td></tr><tr class="even"><td>Schneiderova</td><td>2017</td><td>Czech Republic</td><td>Czechs</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>21‐78</td><td>1057/1405</td><td>KASPar</td><td>6</td><td><a href="#cam42600-bib-0076" data-ref-type="ref">76</a></td><td></td></tr><tr class="odd"><td>rs5275</td><td>Makar (DALS)</td><td>2013</td><td>USA</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>30‐79</td><td>2003/2549</td><td>Illumina™ GoldenGate assay</td><td>6</td><td><a href="#cam42600-bib-0163" data-ref-type="ref">163</a></td></tr><tr class="even"><td>Pereira</td><td>2010</td><td>Portugal</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>50‐75</td><td>115/256</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0100" data-ref-type="ref">100</a></td><td></td></tr><tr class="odd"><td>Siezen (PPHV)</td><td>2006</td><td>Netherlands</td><td>Caucasian</td><td>CRC</td><td>Nested Case‐control</td><td>F/M</td><td>—</td><td>200/388</td><td>PCR‐RFLP</td><td>7</td><td><a href="#cam42600-bib-0164" data-ref-type="ref">164</a></td><td></td></tr><tr class="even"><td>Siezen (DOM)</td><td>2006</td><td>Netherlands</td><td>Caucasian</td><td>CRC</td><td>Nested Case‐control</td><td>F/M</td><td>—</td><td>442/693</td><td>PCR‐RFLP</td><td>6</td><td><a href="#cam42600-bib-0164" data-ref-type="ref">164</a></td><td></td></tr><tr class="odd"><td>Vogel</td><td>2014</td><td>Norway</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>50‐64</td><td>189/399</td><td>KBioscience</td><td>8</td><td><a href="#cam42600-bib-0165" data-ref-type="ref">165</a></td><td></td></tr><tr class="even"><td>Zhang</td><td>2012</td><td>China</td><td>East Asian</td><td>CRC</td><td> </td><td>F/M</td><td>93‐30</td><td>343/340</td><td> </td><td>6</td><td><a href="#cam42600-bib-0101" data-ref-type="ref">101</a></td><td></td></tr><tr class="odd"><td>Cox</td><td>2004</td><td>Spain</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>24‐92</td><td>290/271</td><td>TaqMan</td><td>6</td><td><a href="#cam42600-bib-0166" data-ref-type="ref">166</a></td><td></td></tr><tr class="even"><td>Andersen</td><td>2013</td><td>Denmark</td><td>Caucasian</td><td>CRC</td><td><p>Case‐Cohort</p><p>Study</p></td><td>F/M</td><td>50‐64</td><td>931/1738</td><td>KASPar</td><td>9</td><td><a href="#cam42600-bib-0167" data-ref-type="ref">167</a></td><td></td></tr><tr class="odd"><td>Thompson</td><td>2009</td><td>USA</td><td>Caucasian, African, Other</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>421/480</td><td>TaqMan</td><td>9</td><td><a href="#cam42600-bib-0168" data-ref-type="ref">168</a></td><td></td></tr><tr class="even"><td>Gunter</td><td>2006</td><td>USA</td><td>_</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>43‐74</td><td>210/197</td><td>TaqMan</td><td>8</td><td><a href="#cam42600-bib-0169" data-ref-type="ref">169</a></td><td></td></tr><tr class="odd"><td>Pereira</td><td>2016</td><td>Portugal</td><td>Caucasian</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>50‐75</td><td>191/474</td><td>—</td><td>6</td><td><a href="#cam42600-bib-0170" data-ref-type="ref">170</a></td><td></td></tr><tr class="even"><td>Siezen</td><td>2006</td><td>Netherlands</td><td>Caucasian</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>—</td><td>378/396</td><td>TaqMan</td><td>7</td><td><a href="#cam42600-bib-0171" data-ref-type="ref">171</a></td><td></td></tr><tr class="odd"><td>Vogel</td><td>2014</td><td>Norway</td><td>Caucasian</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>50‐64</td><td>983/399</td><td>KBioscience</td><td>8</td><td><a href="#cam42600-bib-0165" data-ref-type="ref">165</a></td><td></td></tr><tr class="even"><td>Gong</td><td>2009</td><td>USA</td><td>_</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>30‐74</td><td>162/211</td><td>PCR‐RFLP</td><td>8</td><td><a href="#cam42600-bib-0112" data-ref-type="ref">112</a></td><td></td></tr><tr class="odd"><td>Ali</td><td>2005</td><td>USA</td><td>Caucasian</td><td>Adenoma</td><td>Nested Case‐control</td><td>F/M</td><td>55‐74</td><td>749/756</td><td>TaqMan</td><td>7</td><td><a href="#cam42600-bib-0172" data-ref-type="ref">172</a></td><td></td></tr><tr class="even"><td>Ashktorab</td><td>2008</td><td>USA</td><td>African</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>—</td><td>70/136</td><td>TaqMan</td><td>7</td><td><a href="#cam42600-bib-0173" data-ref-type="ref">173</a></td><td></td></tr><tr class="odd"><td>rs4648298</td><td>Iglesias</td><td>2009</td><td>Spain</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>284/123</td><td>PCR‐RFLP</td><td>7</td><td><a href="#cam42600-bib-0114" data-ref-type="ref">114</a></td></tr><tr class="even"><td>Mosallaei</td><td>2018</td><td>Iran</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>88/88</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0049" data-ref-type="ref">49</a></td><td></td></tr><tr class="odd"><td>Ueda</td><td>2008</td><td>Japan</td><td>East Asian</td><td>Adenoma</td><td>Case‐control</td><td>M</td><td>47‐59</td><td>455/1051</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0174" data-ref-type="ref">174</a></td><td></td></tr><tr class="even"><td>Gong</td><td>2009</td><td>USA</td><td>_</td><td>Adenoma</td><td>Case‐control</td><td>F/M</td><td>30‐74</td><td>162/211</td><td>PCR‐RFLP</td><td>8</td><td><a href="#cam42600-bib-0112" data-ref-type="ref">112</a></td><td></td></tr><tr class="odd"><td>rs1801157</td><td>Ramzi</td><td>2014</td><td>Malaysia</td><td>Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>&gt;18</td><td>124/173</td><td>Illumina's BeadArray</td><td>7</td><td><a href="#cam42600-bib-0175" data-ref-type="ref">175</a></td></tr><tr class="even"><td>Razmkhah</td><td>2013</td><td>Iran</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>—</td><td>—</td><td>109/262</td><td>PCR‐RFLP</td><td>4</td><td><a href="#cam42600-bib-0176" data-ref-type="ref">176</a></td><td></td></tr><tr class="odd"><td>Amara</td><td>2015</td><td>Tunis</td><td>African</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>—</td><td>80/80</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0177" data-ref-type="ref">177</a></td><td></td></tr><tr class="even"><td>Dimberg</td><td>2007</td><td>Sweden</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>29‐103</td><td>258/300</td><td>PCR‐RFLP</td><td>5</td><td><a href="#cam42600-bib-0088" data-ref-type="ref">88</a></td><td></td></tr><tr class="odd"><td>Hidalgo‐Pascual</td><td>2007</td><td>Spain</td><td>Caucasian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>35‐87</td><td>151/141</td><td>FRET</td><td>4</td><td><a href="#cam42600-bib-0089" data-ref-type="ref">89</a></td><td></td></tr><tr class="even"><td>Shi</td><td>2013</td><td>Taiwan</td><td>Asian</td><td>CRC</td><td>Case‐control</td><td>F/M</td><td>&gt;30</td><td>349/516</td><td>PCR‐DHPLC</td><td>6</td><td><a href="#cam42600-bib-0090" data-ref-type="ref">90</a></td><td></td></tr></tbody></table>

Different classifications for population subgroup were used for each polymorphism.

John Wiley & Sons, Ltd

For rs731236 in overall meta‐analysis (based on minor allele; t) no significant result for the risk of CRC was observed, but in subgroup analysis in Middle East population the results were significant in heterozygote (Tt vs TT) (0.76 \[0.61‐0.95\]) and overdominant models (Tt vs TT + tt) (0.75 \[0.61‐0.92\]), and borderline significance was observed in dominant model (tt + Tt vs TT) (0.81 \[0.66‐1.00\]) (Figure [2](#cam42600-fig-0002){ref-type="fig"}, Figure [S2](#cam42600-sup-0001){ref-type="supplementary-material"}).

![Forest plot related to rs731236 and risk of CRC. A, Heterozygote model. B, Overdominant model](CAM4-8-7477-g002){#cam42600-fig-0002}

For rs3025039 in overall, there was no significant association, but subgroup analysis revealed significant results (based on minor allele; T). In East Asian population, the allelic model (T vs C) (1.25 \[1.01‐1.54\]) significantly increased the risk of CRC and in dominant model (TT + TC vs CC) (1.29 \[1.00‐1.66\]) there was a trend towards significance (Figure [3](#cam42600-fig-0003){ref-type="fig"}, Figure [S3](#cam42600-sup-0002){ref-type="supplementary-material"}).

![Forest plot related to rs3025039 and risk of CRC. A, Allelic model. B, Dominant model](CAM4-8-7477-g003){#cam42600-fig-0003}

In meta‐analysis for rs3212986, there were significant results in both overall and subgroup analysis in different genetic models (based on minor allele; T), including homozygote model (TT vs GG) 1.76 (1.08‐2.86) (Figure [4](#cam42600-fig-0004){ref-type="fig"}, Figure [S4](#cam42600-sup-0003){ref-type="supplementary-material"}).

![Forest plot related to rs3212986 and risk of CRC. A, Homozygote model. B, TT vs TG model. C, Allelic model. D, Dominant model. E, Recessive model](CAM4-8-7477-g004){#cam42600-fig-0004}

Although we did not find any significant result for rs712 in overall models, subgroup analysis revealed significant and borderline association in Chinese and Czech populations, respectively, on six genetic models (based on minor allele; T), including homozygote model (TT vs GG) in Chinese 2.51 (1.70‐3.69) and in Czech 0.85 (0.72‐1.01) populations (Figure [5](#cam42600-fig-0005){ref-type="fig"}, Figure [S5](#cam42600-sup-0004){ref-type="supplementary-material"}).

![Forest plot related to rs712 and risk of CRC. A, Allelic model. B, Homozygote model. C, Dominant model. D, Recessive model. E, Heterozygote model. F, TT vs TG model](CAM4-8-7477-g005){#cam42600-fig-0005}

The allele (A) of rs1801157 polymorphism increased risk of CRC in Asian population, while we did not find any significant results in Caucasian populations (Table [5](#cam42600-tbl-0005){ref-type="table"}).

###### 

Meta‐analysis of association between rs1801157 and risk of CRC

  Classification      Allelic                  Dominant   Recessive            Overdominant                                                          
  ------------------- ------------------------ ---------- -------------------- -------------- ------------------------- ------- -------------------- -------
  Caucasian (n = 3)   0.98 \[0.82‐1.17\]       .89        1.03 \[0.83‐1.27\]   .90            0.75 \[0.44‐1.26\]        .45     1.09 \[0.88‐1.35\]   .76
  Asian (n = 2)       **2.28 \[1.11‐4.69\]**   .02        2.20 \[0.66‐7.30\]   \<.01          **4.94 \[1.69‐14.42\]**   .58     1.57 \[0.28‐8.88\]   \<.01
  Overall (n = 6)     1.56 \[0.97‐2.50\]       \<.01      1.59 \[0.93‐2.70\]   \<.01          2.03 \[0.73‐5.63\]        \<.01   1.24 \[0.78‐2.00\]   \<.01

  Classification      Homozygote                AA vs AG   Heterozygote (AG vs GG)                                
  ------------------- ------------------------- ---------- ------------------------- ------- -------------------- -------
  Caucasian (n = 3)   0.75 \[0.44‐1.29\]        .50        0.72 \[0.42‐1.25\]        .39     1.07 \[0.86‐1.33\]   .83
  Asian (n = 2)       **4.86 \[1.63‐14.50\]**   .39        **4.96 \[1.59‐15.45\]**   .90     1.78 \[0.38‐8.39\]   \<.01
  Overall (n = 6)     2.31 \[0.73‐7.27\]        \<.01      1.75 \[0.69‐4.40\]        \<.01   1.43 \[0.87‐2.35\]   \<.01

The bold values are statistically significant.

John Wiley & Sons, Ltd

Finally for rs5275 (based on minor allele; C) and rs4648298 (based on minor allele; G), we performed meta‐analysis according to three different subgroup analyses (CRC cases, adenoma, and overall). The results in all different genetic models were not significant except dominant model (0.82 \[0.70‐0.97\]) in adenoma for rs5275, also the allelic model (C vs T) showed borderline association 0.92 (0.85‐1.00) (Tables [6](#cam42600-tbl-0006){ref-type="table"}). For rs4648298 recessive, homozygote, and heterozygote (CG vs GG) models the analysis was not possible, because of zero number in GG genotype in all included studies (Table [7](#cam42600-tbl-0007){ref-type="table"}).

###### 

Meta‐analysis of association between rs5275 and risk of CRC (n = 9) and adenoma (n = 7)

  Classification   Allelic              Dominant   Recessive                Overdominant                                                   
  ---------------- -------------------- ---------- ------------------------ -------------- -------------------- ----- -------------------- -------
  CRC              1.03 \[0.98‐1.09\]   .16        1.03 \[0.92‐1.16\]       .18            1.04 \[0.97‐1.12\]   .38   0.97 \[0.90‐1.04\]   .70
  Adenoma          0.92 \[0.85‐1.00\]   .78        **0.82 \[0.70‐0.97\]**   .19            0.94 \[0.83‐1.05\]   .07   0.90 \[0.71‐1.15\]   \<.01
  Overall          1.00 \[0.95‐1.04\]   .16        0.96 \[0.87‐1.05\]       .05            1.01 \[0.95‐1.08\]   .09   0.95 \[0.86‐1.04\]   .01

  Classification   Homozygote           CC vs CT   Heterozygote (CT vs TT)                                
  ---------------- -------------------- ---------- ------------------------- ------- -------------------- -------
  CRC              1.05 \[0.93‐1.18\]   .13        1.04 \[0.96‐1.13\]        .59     1.01 \[0.90‐1.15\]   33
  Adenoma          0.85 \[0.71‐1.02\]   .38        1.06 \[0.83‐1.36\]        \<.01   0.79 \[0.59‐1.06\]   \<.01
  Overall          0.98 \[0.89‐1.09\]   .10        1.03 \[0.93‐1.14\]        .03     0.88 \[0.76‐1.03\]   .02

The bold values are statistically significant.

John Wiley & Sons, Ltd

###### 

Meta‐analysis of association between rs4648298 and risk of CRC (n = 2) and adenoma (n = 2)

  Classification   Allelic               Dominant/Overdominant/Heterozygote[a](#cam42600-note-0006){ref-type="fn"}                        
  ---------------- --------------------- --------------------------------------------------------------------------- -------------------- -------
  CRC              1.93 \[0.21‐17.52\]   \<.01                                                                       0.47 \[0.04‐5.39\]   \<.01
  Adenoma          1.02 \[0.48‐2.18\]    .99                                                                         0.98 \[0.46‐2.11\]   .99
  Overall          1.41 \[0.49‐4.05\]    \<.01                                                                       1.47 \[0.47‐4.63\]   \<.01

These models had similar results, because of zero number in GG genotype.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42600-sec-0013}
=============

This study aimed to investigate miRNA‐binding site polymorphisms and risk of CRC, which may potentially play roles in various conditions. The effects shown for these polymorphisms associated with miRNA:mRNA interactions. Polymorphisms in miRNA‐binding site can negatively or positively influence these interactions by different mechanisms such as effect of hybrid stability, target sites accessibility, local RNA secondary structure, and structural accessibility. Among 222 included polymorphisms, 25 were eligible for inclusion in our secondary search strategy. Fourteen polymorphisms, with less than four eligible studies, were included in the pooled analysis. The rs17281995 polymorphism is located in 3\'UTR of CD86 gene and binding site of miR‐337 and miR‐582.[22](#cam42600-bib-0022){ref-type="ref"} The minor allele (C) of rs17281995 polymorphism increased the risk of CRC in different genetic models. Although the results are based on limited number of studies but the strong association is noteworthy. This was also observed in the previous review based on two included articles.[129](#cam42600-bib-0129){ref-type="ref"} The nonsignificant results are not conclusive and cannot rule out the association between these polymorphisms and the risk of CRC, because of limited number of included studies and also ethnic differences in studied populations. Further studies need to confirm these results. In addition, seven polymorphisms, with more than four eligible studies, were included in the final meta‐analysis.

The rs731236 polymorphism is located in 3\'UTR of vitamin D receptor gene. Its downregulation is related to cancer progression.[178](#cam42600-bib-0178){ref-type="ref"} There are several previous meta‐analyses on the role of rs731236 on CRC risk. Most of the previous meta‐analyses[179](#cam42600-bib-0179){ref-type="ref"}, [180](#cam42600-bib-0180){ref-type="ref"}, [181](#cam42600-bib-0181){ref-type="ref"}, [182](#cam42600-bib-0182){ref-type="ref"}, [183](#cam42600-bib-0183){ref-type="ref"} found no significant association between the risk of CRC and rs731236. While Serrano et al in their meta‐analysis[184](#cam42600-bib-0184){ref-type="ref"} found significant results based on analyzing both of colorectal cancer and adenoma. Therefore, all previous meta‐analysis results were according to fewer included studies, the overall CRC population and no subgroup analysis were carried out and in some studies adenoma was also included for calculating the risk of CRC. In our study, we carried out subgroup analysis based on different ethnicity and found that the results were different after stratification according to ethnicity. While in overall analysis our results are in line with the previous meta‐analysis, showing no relation between the risk of CRC and rs731236 polymorphism. In Middle East population we observed a significant association between this polymorphism and CRC. This result was not reported previously. We also found a heterozygote advantage for the risk of CRC with heterozygote (Tt) showing protective effects compared with homozygotes (TT, tt). Similarly, in a study on pediatric solid tumor, the heterozygote model decreased the risk of CRC compared to homozygote model. The survival rate of subjects with CRC was significantly decreased in heterozygote model compared to homozygote model.[185](#cam42600-bib-0185){ref-type="ref"} More studies are needed to specify the reason for our interesting observation.

In overall analysis, based on 11 included studies, rs3025039 was not related to the risk of CRC, but is showing association in Caucasian and East Asian populations. Based on subgroup analysis, minor allele in East Asian was related to an increased risk of CRC. This SNP is located in 3\'UTR of vascular endothelial growth factor gene which may affect hsa‐miR‐591 target sites.[186](#cam42600-bib-0186){ref-type="ref"} This gene affects angiogenesis, tumor growth, and metastasis.[187](#cam42600-bib-0187){ref-type="ref"} It is also related to CRC outcomes and treatment.[124](#cam42600-bib-0124){ref-type="ref"} Thus the association between rs3025039 and CRC risk may be related to the effect of this SNP on miRNA:mRNA interactions. However, in the previous meta‐analysis with five included studies, no significant association was found between this polymorphism and risk of CRC.[188](#cam42600-bib-0188){ref-type="ref"} This might be due to heterogeneity of their data in different populations requiring further subgroup analysis.

According to the results based on five included studies, rs3212986 increased the risk of CRC in all genetic models, which was similar to previous meta‐analysis,[189](#cam42600-bib-0189){ref-type="ref"} we also found to the same results in East Asian population. This polymorphism is located in binding site of miR‐15a in 3\'UTR of ERCC1.[72](#cam42600-bib-0072){ref-type="ref"} The polymorphisms and mRNA level of this gene had previously been investigated in CRC.[190](#cam42600-bib-0190){ref-type="ref"}

For rs1801157 minor allele (A) increased risk of CRC was observed in Asian population. This result is similar to previous meta‐analysis by Xu,[191](#cam42600-bib-0191){ref-type="ref"} which found significant association in non‐Caucasian populations. This polymorphism is located in 3\'UTR of CXCL12 in a putative miRNA‐binding site for miR‐941.[192](#cam42600-bib-0192){ref-type="ref"} The effect of CXCL12 polymorphisms on CRC was previously observed in different studies. The CXCL12 binds to CXCR4 and affects different clinical features of cancers such as progression, angiogenesis, and metastasis.[193](#cam42600-bib-0193){ref-type="ref"} Thus the observed association for rs1801157 A allele and CRC may be related to its effect on miRNA:mRNA interactions and CXCL12 expression.

We also found no significant association between rs712 and risk of CRC, in the overall meta‐analysis of five included studies. However, subgroup analysis revealed remarkable and completely different results in Chinese and Czech Republic populations. In Chinese, we observed a strong risk while in Czech population a protective effect was shown in all various models. There is one study similar to our results which confirm the increase risk of this polymorphism in Chinese population.[194](#cam42600-bib-0194){ref-type="ref"} In two other meta‐analyses it has been reported that this polymorphism may increases the overall risk of different types of cancers in the Chinese population.[195](#cam42600-bib-0195){ref-type="ref"}, [196](#cam42600-bib-0196){ref-type="ref"} This variant is within let‐7 KRAS binding site. KRAS, is an important oncogene, which has been previously described to be associated with different types of cancers. This gene influence cancer cells differentiation and proliferation, and is highly mutated in many type of cancers such as CRC.[197](#cam42600-bib-0197){ref-type="ref"}, [198](#cam42600-bib-0198){ref-type="ref"} Based on our results differences between populations should be considered for the effect of this binding site polymorphism in future studies.

In addition, our results (based on 10 eligible studies) showed that rs5275 was not related to the risk of CRC. While the minor allele of rs5275 may have a protective effect on the risk of adenoma. This polymorphism is located in COX‐2 gene at miR‐542‐3p target site. COX‐2 is usually overexpressed in colorectal adenoma patients,[199](#cam42600-bib-0199){ref-type="ref"} and has effect on pro‐inflammatory prostaglandins and links between inflammation and cancer progression.[200](#cam42600-bib-0200){ref-type="ref"} Therefore, the minor allele of rs5275 may be associated with a decreased risk of colorectal adenoma by downregulating COX‐2 expression.

4.1. Strength and limitations {#cam42600-sec-0014}
-----------------------------

Our study had several advantages: First, this is the first systematic review for evaluating the role of miRNA‐binding site polymorphisms on CRC susceptibility, and 25 polymorphisms were included in our pooled analysis. Second, to reduce the publication biases and include all relevant documents we carried out a systematic search on four common databases, as well as other sources such as references of relevant reviews. Third, there was no language bias, we included all relevant documents without any language restriction. Fourth, our study has high power and strength reliability because of our comprehensive and double search strategies and subgroup analyzing based on different ethnicity. Fifth, to reduce binding site false positive prediction, related to bioinformatics tools, we only included polymorphisms located in miRNA‐binding site or 3\'UTR (stated at least in two of the included documents).

There are also some limitations in our study. First, based on insufficient data, it was mandatory to exclude some relevant documents. Second, some polymorphisms had two or three included article. Third, CRC is a multifactorial disease and we only included genetic effect.

5. CONCLUSION {#cam42600-sec-0015}
=============

miRNA‐binding site polymorphisms in this meta‐analysis showed significant association with CRC in different populations. Interestingly, rs731236 polymorphism showed a significant association with CRC in Middle East population with a heterozygote advantage. The minor allele in the East Asian populations for rs3025039, rs3212986, and rs712, and also in Asian population for rs1801157, increased the risk of CRC. The minor allele of rs712 may have a protective effect on the risk of CRC in Czech populations, while rs17281995 showed risk effect in the European population. Finally, it can be concluded that these miRNA‐binding site polymorphisms play different roles on the risk of CRC in various populations which should be considered in data analysis and interpretation in the future studies.
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